Dendrogenin A Reprogramming Immune Environment for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are inadequate in effectively reprogramming the immune environment to enhance anti-tumor responses, particularly in promoting Th1 differentiation, inhibiting immunosuppressive Treg cells, and increasing CD8+ T cell infiltration and activity within tumors.
Innovation Solution
Administration of Dendrogenin A (DDA) to stimulate the production of modified exosomes with anti-tumor properties, promoting Th1 differentiation, maturation of dendritic cells, and enhancing CD8+ T cell activity, while inhibiting Treg cells, thereby reprogramming the immune environment to combat cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments are used, then tumor growth control is achieved, but immune environment reprogramming is insufficient
Solution Approach 1:
The patent changes the chemical parameter by introducing Dendrogenin A, a cholesterol metabolite derivative, to modify the immune microenvironment. This compound specifically alters the differentiation state of immune cells (promoting Th1, inhibiting Treg) and activates anti-tumor immunity, thereby resolving the contradiction between maintaining tumor growth control and achieving adequate immune reprogramming
Solution Approach 2:
The patent uses Dendrogenin A as an intermediary substance that mediates between the existing tumor microenvironment and the desired immune response. This compound acts as a bridge by modulating immune cell function and promoting Th1 differentiation while inhibiting Treg cells, thereby enabling effective immune environment reprogramming without compromising existing tumor growth control
2Productivity
If DDA is administered to promote Th1 differentiation and inhibit Treg cells, then immune response is enhanced, but treatment complexity increases
Solution Approach 1:
The patent employs Dendrogenin A as a multi-functional compound that simultaneously achieves multiple therapeutic objectives: promoting Th1 differentiation, inhibiting Treg cell-mediated immunosuppression, enhancing CD8+ T cell infiltration, and stimulating anti-tumor immunity. This single agent addresses multiple immune dysfunctions in cancer, thereby enhancing immune response while avoiding the complexity of combination therapies
Data Source
AI summary
The present invention relates to methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof. The inventors demonstrated that DDA induces differentiation of tumor cells and stimulates the secretion and the production of modified exosomes with anti-tumor properties (DDA-exosomes) via a mechanism dependent of the expression of the LXRbeta in the parental cells. In particular, one object of the present invention relates to a method of promoting Th1 differentiation and functionality and CD8+ cytotoxicity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of DDA or DDA-exosomes.